AI-powered initiatives aim to enhance customer engagement, accelerate commercial execution, and support long-term growth
Visit Booth #112 at Fontainebleau Miami Beach’s Sparkle Ballroom to watch Milo’s live demonstration.
ROSELAND, N.J., July 15, 2026 (Globe Newswire) — Milestone Scientific, Inc. (NYSE America: MLSS), a medical technology company that develops proprietary precision drug delivery and dynamic pressure sensing® technologies for medical and dental applications, today announced the launch of the first phase of its artificial intelligence (“AI”) strategy. Milo™ announced its AI-enabled digital engagement platform at the American Society for Pain Neuroscience (ASPN) Annual Conference, July 16-18, 2026 in Miami Beach, Florida.
Milo represents the first phase of Milestone’s broader AI strategy and is designed to complement the company’s proprietary technology through intelligent digital engagement, enhanced customer support, and scalable commercial operations. The platform will be pilot demonstrated during ASPN 2026, giving attendees the opportunity to experience Milo and provide feedback to support its continued development.
Initially, Milo is designed to answer common product questions, provide educational information, collect relevant customer information, help qualify leads, and connect healthcare professionals with Milestone’s sales, clinical, and customer support teams.
” Artificial intelligence represents the next evolution of Milestone’s innovation strategy. ” Eric Hines, CEO of Milestone Scientific, said: “Medical professionals are incredibly busy, and not being available the moment a prospect expresses interest can lead to missed opportunities. Milo’s original purpose was to provide instant engagement, answer questions, and make it easy to schedule product demonstrations at a time that fits a prospect’s schedule, such as evenings or weekends. Milo We believe this will enhance the customer experience, accelerate lead conversion, improve sales execution and support the continued growth of our healthcare business.”
Milestone’s AI strategy focuses on four strategic initiatives:
- customer engagement – Intelligent product education, lead qualification, customer support, scheduling, and customer success.
- commercial excellence – Sales and marketing automation, distributor support, CRM integration, commercial analytics.
- clinical innovation – Evaluate AI-enabled software and data-driven capabilities to complement Milestone’s proprietary technology, subject to appropriate validation and regulatory requirements.
- connected medical technology platform – Expand the integration of medical devices, software, data and AI to create a connected digital ecosystem that supports healthcare professionals throughout the customer lifecycle.
We are evaluating future features such as interactive product education, AI-assisted virtual product demonstrations, customer support, order and shipment status, service management, customer analytics, and additional digital tools designed to improve the customer experience.
” Our vision extends beyond customer engagement. ” Hines added. “We see Milo as the foundation of a broader AI platform that complements our proprietary technology throughout the customer journey. Over time, we intend to integrate software, data and artificial intelligence across our commercial and customer support activities as we continue to build a more connected and intelligent health technology company.” ”
Following the ASPN pilot, Milestone plans to leverage customer feedback to inform future development of Milo and its broader AI initiatives.
ASPN 2026 attendees can visit Milestone Scientific’s trade show (Sparkle Ballroom, Booth #112) to experience a Milo pilot demonstration and learn more about the company’s unique precision drug delivery technology.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs and develops innovative injection technologies and devices for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to deliver injections accurately and efficiently, improving overall patient comfort and safety. The company’s proprietary DPS Dynamic Pressure Sensing Technology® instrument is a platform to advance the development of next-generation devices that regulate flow and monitor pressure from the needle tip through platform extensions for subcutaneous drug delivery, including local anesthetics. To learn more, watch the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to execute its business plans, expected revenues, timing of regulatory approvals and future success. Forward-looking statements also include, without limitation, statements regarding the development, capabilities, adoption, timing, integration and expected benefits of Milo and Milestone’s broader artificial intelligence strategy. These statements are subject to risks, including that these efforts may not perform as expected, may be delayed, may not achieve the expected adoption or commercial results, may produce inaccurate or unreliable outputs, may raise data privacy, security or regulatory concerns, and may be dependent on third party AI technology and evolving laws and regulations. These statements involve a number of risks and uncertainties and are based on assumptions that involve judgment regarding future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately, many of which are beyond Milestone’s control. Important factors that could cause actual results to differ materially from those indicated in the forward-looking statements include general economic conditions, failure to achieve anticipated revenue growth, changes in operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and Milestone’s periodic filings with the Securities and Exchange Commission (including, without limitation, Milestone’s annual report for the year ended December 31, 2025) includes risk factors detailed from time to time. The forward-looking statements in this press release are based on management’s reasonable beliefs as of the date of this press release. Milestone undertakes no obligation to publicly revise or update any forward-looking statements for any reason. Coding and payment decisions are determined solely by providers and payers based on applicable laws and policies. Potential Category I designations are determined solely by the American Medical Association and are not guaranteed. Provider is responsible for complying with all applicable billing, coding, and regulatory requirements. Future case submission expectations, reimbursement goals, and revenue estimates referenced herein are based on current program enrollment, advisor commitments, and historical payer activity and are subject to change based on clinical schedules, payer processing timelines, regulatory developments, and other factors. There can be no assurance that Category I designation, targeted redemption levels or projected revenue levels will be achieved.
contact:
Hayden IR:
james carbonara
(646)-755-7412
james@haydenir.com
Brett Mars
(646) 536-7331
Brett@haydenir.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/09cbe963-ad1f-4118-81c6-4edfdcef3bc5.
